Key facts
- This page summarizes Kate Rochlin's Form 4 filing for IN8BIO, INC. (INAB).
- 6 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 07 May 2025, 20:45.
Kate Rochlin - 27 Apr 2025 Form 4 Insider Report for IN8BIO, INC. (INAB)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- INAB
- Reported as of
- 27 Apr 2025
- Net transaction value
- +$2,267
- SEC form
- 4
- Accepted by SEC
- 07 May 2025, 20:45:11 UTC
- Prior SEC filing
- 07 Feb 2025
- Next SEC filing
- 23 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason Minio, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kate Rochlin filed Form 4 for IN8BIO, INC. (INAB) on 07 May 2025.
Change
- Previous filing in this sequence was filed on 07 Feb 2025.
- Current net transaction value: +$2,267.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001898521
Primary reporting owner
Rochlin Kate
- Relationship
- Chief Operating Officer
- Address
- C/O IN8BIO, INC., 350 5TH AVE. SUITE 5330, NEW YORK
- Signature
- /s/ Jason Minio, Attorney-in-Fact
- Signature date
- 07 May 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INAB
transaction
Common Stock
Options Exercise
- Transaction value
- $2,267
- Shares
- +12,295
- Change %
- +29%
- Price
- $0.1844
- Shares after
- 55,169
- Date
- 30 Apr 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INAB
transaction
Derivative
Series A Warrants (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -12,295
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,295
- Exercise price
- $0.4500
- Footnotes
- F1, F2, F3
INAB
transaction
Derivative
Series A Warrants (right to buy)
Award
- Transaction value
- Shares
- +12,295
- Change %
- Price
- Shares after
- 12,295
- Date
- 27 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,295
- Exercise price
- $0.1844
- Footnotes
- F1, F2
INAB
transaction
Derivative
Series A Warrants (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -12,295
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 30 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,295
- Exercise price
- $0.1844
- Footnotes
- F2
INAB
transaction
Derivative
Series B Warrants (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -12,295
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,295
- Exercise price
- $1.50
- Footnotes
- F2, F3, F4
INAB
transaction
Derivative
Series B Warrants (right to buy)
Award
- Transaction value
- Shares
- +12,295
- Change %
- Price
- Shares after
- 12,295
- Date
- 27 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,295
- Exercise price
- $0.4500
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.
Footnote F2
Fully vested and exercisable.
Footnote F3
The reported securities are included within 12,295 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 12,295 shares of common stock.
Footnote F4
The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.